scholarly journals “The state of the heart”: Recent advances in engineering human cardiac tissue from pluripotent stem cells

2015 ◽  
Vol 240 (8) ◽  
pp. 1008-1018 ◽  
Author(s):  
Dario Sirabella ◽  
Elisa Cimetta ◽  
Gordana Vunjak-Novakovic
Keyword(s):  
Stem Cells ◽  
Pluripotent Stem Cells ◽  
Cardiac Tissue ◽  
The State ◽  
Recent Advances ◽  
Human Cardiac Tissue

scholarly journals Advanced maturation of human cardiac tissue grown from pluripotent stem cells

Nature ◽  
2018 ◽  
Vol 556 (7700) ◽  
pp. 239-243 ◽  
Author(s):  
Kacey Ronaldson-Bouchard ◽  
Stephen P. Ma ◽  
Keith Yeager ◽  
Timothy Chen ◽  
LouJin Song ◽  
...  
Keyword(s):  
Stem Cells ◽  
Pluripotent Stem Cells ◽  
Cardiac Tissue ◽  
Human Cardiac Tissue

scholarly journals Author Correction: Advanced maturation of human cardiac tissue grown from pluripotent stem cells

Nature ◽  
2019 ◽  
Vol 572 (7769) ◽  
pp. E16-E17 ◽  
Author(s):  
Kacey Ronaldson-Bouchard ◽  
Stephen P. Ma ◽  
Keith Yeager ◽  
Timothy Chen ◽  
LouJin Song ◽  
...  
Keyword(s):  
Stem Cells ◽  
Pluripotent Stem Cells ◽  
Cardiac Tissue ◽  
Human Cardiac Tissue

scholarly journals Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells

2016 ◽  
Vol 17 (2) ◽  
pp. 256 ◽  
Author(s):  
Mohammed Kawser Hossain ◽  
Ahmed Abdal Dayem ◽  
Jihae Han ◽  
Subbroto Kumar Saha ◽  
Gwang-Mo Yang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Drug Discovery ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Disease Modeling ◽  
Recent Advances ◽  
Induced Pluripotent

Abstract 341: Transplantation of Cardiac Tissue Sheets Including Defined Cardiovascular Cell Populations Differentiated from Human-Induced Pluripotent Stem Cells Ameliorates Cardiac Dysfunction After Subacute Myocardial Infarction

2012 ◽  
Vol 111 (suppl_1) ◽  
Author(s):  
Hidetoshi Masumoto ◽  
Tadashi Ikeda ◽  
Tatsuya Shimizu ◽  
Teruo Okano ◽  
Ryuzo Sakata ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Stem Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Cardiac Dysfunction ◽  
Cardiac Tissue ◽  
Vascular Endothelial Cell ◽  
Cell Populations ◽  
Cardiac Cell ◽  
Induced Pluripotent

BACKGROUNDS: To realize cardiac regeneration with human induced pluripotent stem cells (hiPSCs), efficient differentiation from hiPSCs to defined cardiac cell populations (cardiomyocytes [CMs]/ endothelial cells [ECs]/ vascular mural cells [MCs]), and transplantation technique for fair engraftment are required. Recently, we reported that mouse ES cell-derived cardiac tissue sheet transplantation to rat myocardial infarction (MI) model ameliorated cardiac function after MI (Stem Cells, in press). Here we tried to extend this technique to hiPSCs. METHODS & RESULTS: We have reported an efficient cardiomyocyte differentiation protocol based on a monolayer culture (PLoS One, 2011), in which cardiac troponin-T (cTnT)-positive CMs robustly appeared with 50-80% efficiency. In this study, we further modified the protocol to induce vascular cells (ECs/MCs) together with CMs by vascular endothelial cell growth factor supplementation, resulted in proportional differentiation of cTnT+-CMs (62.7±11.7% of total cells), VE-cadherin+-ECs (7.8±4.9%) and PDGFRb+-MCs (18.2±11.0%) at differentiation day 15 (n=12). Then, these cells were transferred onto temperature-responsive culture dishes (UpCell dishes; CellSeed, Tokyo, Japan) to form cardiac tissue sheets including defined cardiac populations. After 4 days of culture, we successfully collected self-pulsating cardiac tissue sheets with 7.0×10 5 ±2.3 (n=12) of cells consisted of CMs (46.9±15.9% of total cells), ECs (4.1±3.7%), and MCs (22.5±15.7%). Three-layered hiPSC-derived cardiac sheets were transplanted to a MI model of athymic rat heart one week after MI. In transplantation group, echocardiogram showed a significant improvement of systolic function of left ventricle (fractional shortening: 22.6±5.0 vs 36.5±8.0%, p<0.001, n=20) and a decrease in akinetic length (20.8±9.7 vs 2.5±7.7%, p<0.001, n=20) (pre-treatment vs 4weeks after transplantation). We also succeeded in generation of larger sheets (1.6 inch diameter) with the same method. CONCLUTIONS: Transplantation of hiPSC-derived cardiac tissue sheets significantly ameliorates cardiac dysfunction after MI. Thus, we developed a valuable technological basis for hiPSC-based cardiac cell therapy.

Human cardiac tissue induces transdifferentiation of adult stem cells towards cardiomyocytes

Cytotherapy ◽  
2010 ◽  
Vol 12 (3) ◽  
pp. 332-337 ◽  
Author(s):  
Macarena Perán ◽  
Juan A. Marchal ◽  
Elena López ◽  
Manuel Jiménez-Navarro ◽  
Houria Boulaiz ◽  
...  
Keyword(s):  
Stem Cells ◽  
Adult Stem Cells ◽  
Cardiac Tissue ◽  
Human Cardiac Tissue

Regenerative Medicine/Cardiac Cell Therapy: Pluripotent Stem Cells

2017 ◽  
Vol 66 (01) ◽  
pp. 053-062 ◽  
Author(s):  
Ana Duran ◽  
Olivia Reidell ◽  
Harald Stachelscheid ◽  
Kristin Klose ◽  
Manfred Gossen ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cell Therapy ◽  
Pluripotent Stem Cells ◽  
Cardiac Tissue ◽  
Cellular Reprogramming ◽  
Patient Specific ◽  
Cellular Cardiomyoplasty ◽  
Somatic Cell Therapy ◽  
Cardiac Cell Therapy ◽  
Induced Pluripotent

AbstractFor more than 20 years, tremendous efforts have been made to develop cell-based therapies for treatment of heart failure. However, the results of clinical trials using somatic, nonpluripotent stem or progenitor cells have been largely disappointing in both cardiology and cardiac surgery scenarios. Surgical groups were among the pioneers of experimental and clinical myocyte transplantation (“cellular cardiomyoplasty”), but little translational progress was made prior to the development of cellular reprogramming for creation of induced pluripotent stem cells (iPSC). Ever since, protocols have been developed which allow for the derivation of large numbers of autologous cardiomyocytes (CMs) from patient-specific iPSC, moving translational research closer toward clinical pilot trials. However, compared with somatic cell therapy, the technology required for safe and efficacious pluripotent stem cell (PSC)-based therapies is extremely complex and requires tremendous resources and close interactions between basic scientists and clinicians. This review summarizes PSC sources, strategies to derive CMs, current cardiac tissue engineering approaches, concerns regarding immunogenicity and cellular maturity, and highlights the contributions made by surgical groups.

Sign in / Sign up

Export Citation Format

Share Document